Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Shares Issued (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Shares Issued for 5 consecutive years, with $3000.0 as the latest value for Q2 2025.

  • On a quarterly basis, Shares Issued changed N/A to $3000.0 in Q2 2025 year-over-year; TTM through Sep 2025 was $24000.0, a 111.11% increase, with the full-year FY2023 number at $78000.0, down 80.55% from a year prior.
  • Shares Issued was $3000.0 for Q2 2025 at Whitehawk Therapeutics, down from $21000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $145.4 million in Q3 2021 to a low of -$155.0 million in Q4 2021.
  • A 4-year average of -$699769.2 and a median of $21000.0 in 2025 define the central range for Shares Issued.
  • Biggest YoY gain for Shares Issued was 629.63% in 2023; the steepest drop was 162.25% in 2023.
  • Whitehawk Therapeutics' Shares Issued stood at -$155.0 million in 2021, then soared by 100.22% to $347000.0 in 2022, then plummeted by 162.25% to -$216000.0 in 2023, then soared by 101.39% to $3000.0 in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Shares Issued are $3000.0 (Q2 2025), $21000.0 (Q1 2025), and -$216000.0 (Q4 2023).